

Seminar

The non-genomic mechanism of nuclear receptor targeting mitochondria and its application in drug discovery

[Speaker]

Prof. Xiaokun Zhang

[Time]

2:00-3:30PM, June 5, 2017

[Host]

Prof. Guangxun Meng

[Venue]

A201, Life Science Research Building

[Speaker Introduction]

 Dean of the school of pharmaceutical science, Xiamen University, Cheung Kong Scholar Lecture Professor, National Thousand Talents Program

[Research Focus]

Dr. Zhang studies the chemopreventive and therapeutic effects of Vitamin A and its synthetic analogs in various cancers and other diseases. He discovered a new vitamin A signaling pathway through RXR protein complexes. An agent that modulates RXR activities has been approved by the FDA for treating lymphoma patients and is now in phase III clinical trial for lung cancer. Dr. Zhang also found that a gene that binds Vitamin A (called RARb) acts as a tumor suppressor. His group recently discovered a new paradigm for destroying cancer cells using a protein called Nur77, which is often present at high levels in cancer cells to promote their growth. A series of important findings about Nur77 have been found by Xiaokun Zhang recently.